Overview
Nakul Shekhawat, M.D., M.P.H. is an ophthalmologist and eye surgeon at the Johns Hopkins Wilmer Eye Institute and the 2023 Stephen F Raab and Mariellen Brickley-Raab Rising Professor of Ophthalmology. He specializes in cataract surgery, complex cataract and anterior segment surgery, corneal and external diseases, and corneal surgery including both full- and partial-thickness corneal transplantation (DMEK, DSAEK, DALK, PKP). Dr. Shekhawat received his M.D. degree from Vanderbilt University School of Medicine and his M.P.H. degree in epidemiology and biostatistics from the Johns Hopkins Bloomberg School of Public Health. He completed ophthalmology residency at the renowned Kellogg Eye Center, University of Michigan where he received the Resident Excellence Award from the American Society of Cataract and Refractive Surgery. He completed additional subspecialty training in cornea, external disease, and refractive surgery at the Wilmer Eye Institute where he was awarded the prestigious Claes Dohlman Award from Harvard Medical School recognizing the most outstanding cornea fellow in the country. CV https://www.hopkinsmedicine.org/-/media/wilmer/documents/cvs/Shekhawat_CV.pdf Recent News Articles and Media Coverage Laser cataract surgery now offered in Bethesda- Hopkins Medicine (April 2024) Johns Hopkins, Microsoft Extend Collaboration for Startups as Newest Grant Recipients Named - Johns Hopkins Technology Ventures (July 2021) Taking a Wide View with Nakul Shekhawat - Hopkins Medicine (September 2020) A Patient’s Guide to Shingles: Prompt treatment is crucial to avoid severe neurological complications - US News & World Report (January 2020) Shingle White Female: Study finds three-fold increase in number of Americans diagnosed with shingles - The Ophthalmologist (July 2019).
Dr. Shekhawat is highly rated in 4 conditions, according to our data. His top areas of expertise are Interstitial Keratitis, Cataract, Amebiasis, Cataract Removal, and Vitrectomy.
His clinical research consists of co-authoring 42 peer reviewed articles. MediFind looks at clinical research from the past 15 years.
Insurance
Accepted insurance can change. Please verify directly with the provider.
Accepted insurance plans:
- EPO
- HMO
- POS
- PPO
- EPO
- HMO
- POS
- PPO
- INSURANCE PLAN
- MANAGED MEDICAID PLAN
- MEDICARE MAPD
- OTHER MEDICARE PART D
- PPO
- HMO
- POS
- PPO
- EPO
- HMO
- PPO
- INSURANCE PLAN
- MEDICARE PDP
- PPO
- HMO
- POS
- PPO
- HMO
- INSURANCE PLAN
- MANAGED MEDICAID PLAN
- MEDICARE MAPD
- MEDICARE PDP
- MEDICARE SNP
- OTHER COMMERCIAL
- OTHER MEDICARE
- OTHER MEDICARE PART D
- PPO
- EPO
- HMO
- PPO
- HMO
- INDEMNITY
- POS
- PPO
- EPO
- POS
- PPO
- HMO
- MANAGED MEDICAID PLAN
- MEDICARE MAPD
- MEDICARE-MEDICAID PLAN
- OTHER MANAGED MEDICAID
- OTHER MEDICAID
- STATE MEDICAID
- INSURANCE PLAN
- MANAGED MEDICAID PLAN
- MEDICARE MAPD
- MEDICARE PDP
- MEDICARE SNP
- MEDICARE-MEDICAID PLAN
- OTHER MEDICARE PART D
- EPO
- HMO
- POS
- PPO
- EPO
- HMO
- INSURANCE PLAN
- MANAGED MEDICAID PLAN
- MEDICARE MAPD
- MEDICARE PDP
- MEDICARE SNP
- MEDICARE-MEDICAID PLAN
- OTHER MEDICARE
- OTHER MEDICARE PART D
Locations
Maumenee Lobby, Baltimore, MD 21287
6430 Rockledge Drive, Building 6, Bethesda, MD 20817
Clinical Research
Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.
The Johns Hopkins Hospital
Peter A. Campochiaro, M.D. is the George S. and Dolores Doré Eccles Professor of Ophthalmology and Neuroscience at the Wilmer Eye Institute, Johns Hopkins University School of Medicine. He is a clinician-scientist who directs a research laboratory and conducts clinical trials. His laboratory research is directed at understanding the pathogenesis of ocular neovascularization and excessive retinal vascular permeability, and the mechanism of cone cell death in inherited retinal degenerations. He helped to determine the importance of vascular endothelial growth factor (VEGF), hypoxia-inducible factor-1, and Tie2 in retinal and choroidal vascular diseases. The clinical trial group under Dr. Campochairo provided the first demonstration of the benefits of suppression of VEGF in diabetic macular edema and retinal vein occlusion. He has developed strategies for sustained suppression of VEGF that are currently being tested in clinical trials. Dr. Campochiaro trained at the University of Notre Dame, Johns Hopkins School of Medicine, and the University of Virginia. He did a vitreoretinal fellowship and research fellowships at Johns Hopkins and joined the faculty of the University of Virginia in 1984. He became professor of Ophthalmology and Neuroscience at the Wilmer Eye Institute, Johns Hopkins in 1991. Dr. Campochiaro is highly rated in 18 conditions, according to our data. His top areas of expertise are Retinal Vein Occlusion, Late-Onset Retinal Degeneration, Age-Related Macular Degeneration (ARMD), Trabeculectomy, and Vitrectomy.
The Johns Hopkins Hospital
Dr. Neil Bressler has been a member of the Wilmer Eye Institute's faculty since 1988 and is the inaugural James P. Gills Professor of Ophthalmology. He specializes in retinal diseases, with special interests in diabetic retinopathy and macular degeneration. Dr. Bressler's main research interests have been collaborative efforts in clinical trials of common retinal diseases, including age-related macular degeneration and diabetic retinopathy, having chaired several NIH-sponsored and industry-sponsored multicenter randomized clinical trials and authored almost 300 peer-reviewed publications. He is a past chair of the NIH-sponsored Diabetic Retinopathy Clinical Research Network, and was responsible for guidelines, policies, protocol development as well as implementation, and to facilitate Network operations in a way that maintains academic integrity and optimal clinical trial performance. He also has chaired the National Eye Institutes Data and Safety Monitoring Committee for intramural clinical trials and the FDA Ophthalmic Devices Panel. Dr. Bressler is currently editor-in-chief of JAMA Ophthalmology. Dr. Bressler is highly rated in 18 conditions, according to our data. His top areas of expertise are Diabetic Macular Edema (DME), Age-Related Macular Degeneration (ARMD), Late-Onset Retinal Degeneration, Vitrectomy, and Cataract Removal.
Greater Baltimore Medical Center Inc
Janet Sunness is an Ophthalmologist in Baltimore, Maryland. Dr. Sunness is highly rated in 16 conditions, according to our data. Her top areas of expertise are Stargardt Macular Degeneration, Geographic Atrophy, Late-Onset Retinal Degeneration, and Age-Related Macular Degeneration (ARMD). Dr. Sunness is currently accepting new patients.
Areas of Expertise
MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.
Learn more about MediFind’s expert tiers
- Advanced
- AmebiasisDr. Shekhawat isAdvanced. Learn about Amebiasis.
- CataractDr. Shekhawat isAdvanced. Learn about Cataract.
- Cataract RemovalDr. Shekhawat isAdvanced. Learn about Cataract Removal.
- Interstitial KeratitisDr. Shekhawat isAdvanced. Learn about Interstitial Keratitis.
- Experienced
- AstigmatismDr. Shekhawat isExperienced. Learn about Astigmatism.
- Conjunctivitis (Pink Eye)Dr. Shekhawat isExperienced. Learn about Conjunctivitis (Pink Eye).
- Corneal TransplantDr. Shekhawat isExperienced. Learn about Corneal Transplant.
- EndophthalmitisDr. Shekhawat isExperienced. Learn about Endophthalmitis.
- Fuchs DystrophyDr. Shekhawat isExperienced. Learn about Fuchs Dystrophy.
- GlaucomaDr. Shekhawat isExperienced. Learn about Glaucoma.